Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Q1 2025 Management View CEO Reshma Kewalramani highlighted $2.77 billion in revenue for Q1 2025, reflecting 3% growth compared to the prior year. The company focused on diversifying revenue through ...

“VRTX has compelling long-term growth prospects, but it is difficult to predict Journavx performance near-term.” On a ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded rating to 'Buy.' Discover why!

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 0.95%) on Casgevy. Although Vertex takes a ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend.

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. In addition, Vertex revealed that ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Iovance Therapeutics' tumor-infiltrating lymphocyte therapies have tremendous ...